Traitement de l'osteoporose postmenopausique en 2004

[en] Major improvements have been observed, during the last ten years, in the management of postmenopausal osteoporosis. The most significant benefits have been obtained through the availability of new medications which have demonstrated their anti-fracture efficacy in the course of well conducted, scientifically sound studies. Due to the pharmacological properties of these new medications, treatment of osteoporosis can now be tailored to the needs of each and every single postmenopausal woman. Calcium supplementation (500 mg/day) should be offered to all post menopausal women unless dietary records show a sufficient intake. On the grounds of the high prevalence of low serum vitamin D levels in the ederly Belgian population, the systematic use of a calcium-vitamin D combination, after the age of 65 years, appears to be justified. Raloxifene is an interesting option for women with low mineral density or prevalent vertebral fractures. This molecule has demonstrated unequivocal anti-fracture efficacy at the level of the spine and is also caracterized by a beneficial effect on non-spinal fractures, in high risk women. Bisphosphonates (alendronate and risedronate) have shown the anti-fracture efficacy at the level of the axial and appendicular skeleton. The availability of a weekly formulation improves their compliance, notwithstanding the constrains related to the potential upper gastro-intestinal toxicity of these compounds. Bisphosphonates appear to be the first-line choice for patients with more severe osteoporosis and high risk to develop hip fractures. Teriparatide (1-34 Fragment of parathyroid hormone) is a new pharmacological option, oriented, mainly if not exclusively because of its parenteral administration and high cost, to patients with severe osteoporosis (low bone density and prevalent vertebral fracture(s). Strontium ranelate offers an anti-fracture efficacy at all skeleton sites and an oustanding overall tolerance and may play a main role in the future management of osteoporosis.

Disciplines :

General & internal medicine

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Devogelaer, Jean-Pierre

Language :

French

Title :

Traitement de l'osteoporose postmenopausique en 2004

Alternative titles :

[en] Treatment of Postmenopausal Osteoporosis in 2004

Publication date :

November 2004

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

633-47

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 October 2009

Statistics

Number of views

145 (6 by ULiège)

Number of downloads

157 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Johnell O, Kanis JA, Oden A et al.- Mortality after osteoporotic fractures. Osteoporos Int, 2004, 15, 38-42.
Salkeld G, Cameron ID, Cumming RG, et al.- Quality of life related to fear of falling and hip fracture in older women: A time trade off study. Bmj, 2002, 320, 241-6.
Reginster JY, Gillet P, Ben Sedrine W, et al.- Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics, 1999, 18, 507-14.
Gillet P, Reginster JY.- Increased number of hip fractures. Lancet, 1999, 353, 2180-1.
Kanis J, Oden A, Johnell O, et al.- Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int, 2004, 15, 108-12.
Brazier JE, Green C, Kanis JA.- A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int, 2002, 13, 768-76.
Cockerill W, Lunt M, Silman AJ, et al.- Health-related quality of life and radiographic vertebral fracture. Osteoporos Int, 2004, 15, 113-9.
Johnell O, Kanis JA, Oden A, et al.- Fracture risk following an osteoporotic fracture. Osteoporos Int, 2004, 15, 175-9.
Kanis JA.- Diagnosis of osteoporosis and assessment of fracture risk. Lancet., 2002, 359, 1929-36.
Kanis JA, Johnell O, Oden A, et al.- Ten-year probabilities of osteoporotic fractures according to bmd and diagnostic thresholds. Osteoporos Int, 2001, 12, 989-95.
Devogelaer J.- How do you know who needs prevention or treatment? Baillières Clin Rheum, 1997, 11, 539-63.
Report of a who study group.- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Technical Report Ser, 1994, 843, 1-129.
Kanis JA, Devogelaer JP, Gennari C.- Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: A position paper of the european foundation for osteoporosis and bone disease. Osteoporos Int, 1996, 6, 256-61.
Boonen S, Kaufman JM, Reginster JY, et al.- Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatment in Belgium. Osteoporos Int, 2003, 14, 110-5.
Cranney A, Guyatt G, Griffith L, et al.- Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews, 2002, 23, 570-8.
Million Women Study Collaborators.- Breast cancer and hormone-replacement therapy in the million women study. Lancet, 2003, 362, 419-27.
Cauley JA, Robbins J, Chen Z, et al.- Effects of estrogen plus progestin on risk of fracture and bone mineral density, the women's health initiatives randomized trial. Jama, 2003, 290, 1729-38.
Tosteson AN, Grove MR, Hammond CS, et al.- Early discontinuation of treatment for osteoporosis. Am J Med, 2003, 115, 209-16.
Yood RA, Emani S, Reed JI, et al.- Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int, 2003, 14, 965-8.
Reginster JY, Deroisy R, Sarlet N, et al.- Relation between calcium intake during different periods of life and bone mineral content at the menopause. Osteoporosis 1990. C. Christiansen And K. Overgaard Eds. Osteoporosis Aps Publ., Copenhagen 1990, Pp 400-401.
Reginster JY, Deroisy R, Pirenne H, et al.- High prevalence of low femoral bone mineral density in elderly women living in nursing homes or community-dwelling: A plausible role of increased parathyroid hormone secretion. Osteoporos Int, 1999, 9, 121-8.
Dawson-Hughes B, Harris SS, et al.- Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 1997, 670-6.
Chapuy MC, Arlot ME, Delmas PD, et al.- Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Bmj, 1994, 308, 1081-2.
Lips P, Graafmans WC, Ooms ME, et al.- Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Inter Med, 1996, 124, 400-6.
Trivedi DP, Doll R, Khaw KT.- Effect of four monthly oral vitamin D3 (Cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. Bmj, 2003, 326, 469-74.
Deroisy R, Zartarian M, Meurmans L, et al.- Acute changes in serum calcium and parathyroid hormone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers. Clin Rheumatol, 1997, 16, 249-53.
Boonen S, Rizzoli R, Meunier PJ, et al.- The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: A consensus report. Osteoporos Int, 2004. Accept in print.
Riggs BL, Hartmann LC.- Selective estrogen-receptor modulators - Mechanisms of action, Application to clinical practice. N Engl J Med, 2003, 348, 618-29.
Lufkin EG, Whitaker MD, Nickelsen T, et al.- Treatment of established postmenopausal osteoporosis with Raloxifene: A randomized trial. J Bone Miner Res, 1998, 13, 1747-54.
Ettinger B, Black DM, Mitlak BH, et al.- Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene. Results from a 3-year randomized clinical trial. Jama, 1999, 282, 637-45.
Maricic M, Adachi JD, Sarkar S, et al.- Early effects of Raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med, 2002, 162, 1140-3.
Delmas PD, Genant HK, Crans GG, et al.- Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the more trial. Bone, 2003, 33, 522-32.
Siris E, Adachi JD, Lu Y, et al.- Effects of Raloxifene on fracture severity in postmenopausal women with osteoporosis: Results from the more study. Osteoporos Int; 2002, 13, 907-13.
Kanis JA, Johnell O, Black DM, et al.- Effect of Raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the multiple outcomes of Raloxifene evaluation trial. Bone, 2003, 33, 293-300.
Delmas PD, Ensrud KE, Adachi JD, et al.- Efficacy of Raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab, 2002, 87, 3609-17.
Hochberg MC, Ross PD, Black D, et al.- Larger increases in bone mineral density during Alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum, 1999, 42, 1246-54.
Sarkar S, Mitlak BH, Wong M, et al.- Relationships between bone mineral density and incident vertebral fracture risk with Raloxifene therapy. J Bone Min Res, 2002, 17, 1-10.
Reginster JY, Sarkar S, Zegels B, et al.- Reduction in pinp, a marker of bone metabolism, with Raloxifene treatment and its relationship with vertebral fracture risk. Bone, 2004, 34, 344-51.
Bjarnason NH, Sarkar S, Duong T, et al.- Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of Raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int, 2001, 12, 922-30.
Cummings SR, Eckert S, Krueger KA, et al.- The effect of Raloxifene on risk of breast cancer in postmenopausal women. Jama, 1999, 281, 2189-97.
Barrett-Connor E, Grady D, Sashegyi A, et al.- Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the «MORE» (Multiple Outcomes Of Raloxifene Evaluation) Randomized trial. Jama, 2002, 287, 847-57.
Reginster JY.- Les Bisphosphonates. Rev Med Liège, 1996, 51, 120-2.
Devogelaer JP.- Clinical use of Bisphosphonates. Curr Opin Rheumatol, 1996, 8, 384-91.
Reginster JY, Devogelaer JP, Kaufman JM, et al.- L'ostéoporose d'involution chez la femme. Rev Med Liège, 1999, 54, 335-40.
Liberman UA, Weiss SR, Broll J, et al.- Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med, 1995, 333, 1437-43.
Black DM, Cummings SR, Karpf DB, et al.- Randomised trial of effect of Alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 1996, 348, 1535-41.
Ensrud KE, Black DM, Palermo L, et al.- Treatment with Alendronate prevents fractures in women at highest risk. Arch Intern Med, 1997, 157, 2617-24.
Cummings SR, Black DM, Thompson DE, et al.- Effect of Alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. Jama, 1998, 280, 2077-82.
Karpf DB, Shapiro DR, Seeman E, et al.- Prevention of nonvertebral fractures by Alendronate. A meta-analysis. Jama, 1997, 277, 1159-64.
De Groen PC, Lubbe DF, Hirsch LJ, et al.- Esophagitis associated with the use of alendronate. N Engl J Med, 1996, 335, 1016-21.
Ettinger B, Pressman A, Schein J, et al.- Connolly. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Managed Care Pharmacy, 1998, 4, 488-91.
Greenspan SL, Bone Iii G, Schnitzer TJ, et al.- Two-year results of once-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis. The Alendronate once-weekly study group. J Bone Min Res, 2002, 17, 1988-96.
Simon JA, Lewiecki EM, Smith ME, et al.- Patient preference for once-weekly Alendronate 70 mg versus once-daily Alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Therapeut, 2002, 24, 1871-86.
Bagger YZ, Tanko LB, Alexandersen P, et al.- Alendronate has a residual effect on bone mass in postmenopausal danish women up to 7 years after treatment withdrawal. Bone, 2003, 33, 301-7.
Bone HG, Hosking D, Devogelaer JP, et al.- Ten years' experience with Alendronate for osteoporosis in postmenopausal women. N Engl J Med, 2004, 350, 1189-99.
Harris ST, Watts NB, Genant HK, et al.- Effects of Risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. Jama, 1999, 282, 1344-52.
Reginster JY, Minne HW, Sorensen OH, et al.- Randomized trial of the effects of Risedronate on vertebral Fractures In Women With Established Postmenopausal osteoporosis. Osteoporos Int, 2000, 11, 83-91.
Heaney RP, Zizic TM, Fogelman I, et al.- Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteopors Int, 2002, 13, 501-5.
Mcclung MR, Geusens P, Miller PD, et al.- Effect of Risedronate on the risk of hip fracture in elderly women. N Engl J Med, 2001, 344, 333-40.
Harrington JT, Ste-Marie LG, Brandi ML, et al.- Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int, 2004, 74, 129-35.
Sorensen OH, Crawford GM, Mulder H, et al.- Long-term efficacy of Risedronate: A 5-year placebo-controlled clinical experience. Bone, 2003, 32, 120-6.
Thomson ABR, Marshall JK, Hunt RH, et al.- 14 day endoscopy study comparing Risedronate and Alendronate in postmenopausal women stratified by helicobacter pylori status. J Rheum, 2002, 29, 1965-74.
Lanza FL, Hunt RH, Thomson ABR, et al.- Endoscopic comparison of esophageal and gastroduodenal effects of Risedronate and Alendronate in postmenopausal women. Gastroenterology, 2000, 119, 631-8.
Lanza F, Schwartz H, Sahba B, et al.- An endoscopic comparison of the effects of Alendronate and Risedronate on upper gastrointestinal mucosae. Am J Gastroenterol, 2000, 95, 3112-7.
Brown JP, Kendler DL, Mcclung MR, et al.- The efficacy and tolerability of Risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int, 2002, 71, 103-11.
Watts NB, Lindsay R, Kasibhatl ZI, et al.- Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week Risedronate. Osteoporos Int, 2003, 14, 437-41.
Hosking D, Adami S, Felsenberg D, J et al.- Comparison of change in bone resorption and bone mineral density with once-weekly Alendronate and daily Risedronate: A randomised, placebo-controlled study. Curr Med Res Opin, 2003, 19, 383-94.
Weinstein RS.- True strength. J Bone Min Res, 2000, 15, 621-5.
Mashiba T, Hirano T, Turner CH, et al.- Suppressed bone turnover by Bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Min Res, 2000, 15, 613-20.
Eastell R, Barton I, Hannon RA, et al.- Relationship of early changes in bone resorption to the reduction in fracture risk with Risedronate. J Bone Min Res, 2003, 18, 1051-6.
Reginster JY, Taquet AN, Fraikin G, et al.- Parathyroid hormone in the treatment of involutional osteoporosis: Back to the future. Osteoporos Int, 1997, 7, S163-7.
Neer RM, Arnaud CD, Zanchetta JR, et al.- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344, 1434-41.
Marcus R, Wang O, Satterwhite J et al.- The skeletal response to Teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Min Res, 2003, 18, 18-23.
Lindsay R, Scheels WH, Neer R et al.- Sustained vertebral fracture risk reduction after withdrawal of Teriparatide (recombinant human parathyroid hormone (1-34)) in postmenopausal women with osteoporosis. Arch Int Med, 2004, Accepted In Print.
Body JJ, Gaich GA, Scheele WH, et al.- A randomized double-blind trial to compare the efficacy of Teriparatide (recombinant human parathyroid hormone (1-34)) with Alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab, 2002, 87, 4528-35.
Black DM, Greenspan SL, Ensrud KE, et al.- The effects of parathyroid hormone and Alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med, 2003, 349, 1207-15.
Kholsa S.- Parathyroid hormone plus Alendronate A combination that does not add up. N Engl J Med, 2003, 349, 1277-9.
Reginster JY.- Strontium Ranelate in osteoporosis. Current Pharmaceutical Design, 2002, 8, 1907-16.
Meunier PJ, Roux C, Seeman E, et al.- The effects of Strontium Ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med, 2004, 350, 459-668.